Measured Wealth Private Client Group LLC Buys Shares of 1,826 Krystal Biotech, Inc. $KRYS

Posted by Brenda Bartman on Jul 23rd, 2026

Measured Wealth Private Client Group LLC acquired a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) during the 1st quarter, Holdings Channel.com reports. The firm acquired 1,826 shares of the company’s stock, valued at approximately $472,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of KRYS. Royal Bank of Canada boosted its stake in Krystal Biotech by 145.2% during the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after acquiring an additional 964 shares during the last quarter. AQR Capital Management LLC grew its holdings in Krystal Biotech by 29.9% during the first quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock valued at $2,187,000 after purchasing an additional 2,792 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Krystal Biotech by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after purchasing an additional 688 shares in the last quarter. Empowered Funds LLC bought a new stake in Krystal Biotech in the first quarter valued at approximately $218,000. Finally, Cetera Investment Advisers raised its holdings in Krystal Biotech by 107.9% in the second quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock worth $597,000 after purchasing an additional 2,255 shares during the period. 86.29% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on KRYS. Jefferies Financial Group reiterated a “buy” rating and set a $474.00 target price on shares of Krystal Biotech in a report on Monday, July 13th. Citigroup increased their price target on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Bank of America raised their price target on Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. HC Wainwright lifted their price objective on Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a report on Tuesday, June 16th. Finally, Weiss Ratings lowered Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, July 1st. Ten analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Krystal Biotech has a consensus rating of “Moderate Buy” and a consensus price target of $360.67.

View Our Latest Report on Krystal Biotech

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $336.80 on Thursday. The company’s 50-day moving average price is $332.97 and its two-hundred day moving average price is $291.66. Krystal Biotech, Inc. has a one year low of $130.50 and a one year high of $382.54. The stock has a market capitalization of $9.93 billion, a PE ratio of 45.03 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last posted its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, beating analysts’ consensus estimates of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The firm had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. On average, analysts anticipate that Krystal Biotech, Inc. will post 7.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of Krystal Biotech stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the transaction, the executive vice president directly owned 1,000 shares of the company’s stock, valued at $347,270. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the sale, the insider directly owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. The trade was a 1.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 26,642 shares of company stock worth $8,243,923 over the last three months. 13.10% of the stock is owned by insiders.

Krystal Biotech Company Profile

(Free Report)

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.